209 related articles for article (PubMed ID: 30504329)
1. Optimizing quality care for the oral vitamin K antagonists (VKAs).
Pengo V; Denas G
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):332-338. PubMed ID: 30504329
[TBL] [Abstract][Full Text] [Related]
2. [Therapy education for patients receiving oral anti-coagulants vitamin K antagonists].
Satger B; Blaise S; Fontaine M; Yver J; Allenet B; Baudrant M; Pernod G; Bosson JL
Presse Med; 2009 Dec; 38(12):1780-7. PubMed ID: 19815369
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the impact of a training program on vitamin K antagonists (VKA) implemented by pharmacy students aiming at improving the knowledge of patients receiving vitamin K antagonists during their hospital clinical training course].
Conort O; Siguret V; Bourdon O; Nazaraly S; Brignone M; Pons-Kerjean N; Houze S; Laribe Cage S; Berthet F; Golmard JL; Brion F; Tilleul P
Ann Pharm Fr; 2014 Jul; 72(4):287-95. PubMed ID: 24997889
[TBL] [Abstract][Full Text] [Related]
4. Reversing vitamin K antagonists: making the old new again.
Eichinger S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):605-611. PubMed ID: 27913535
[TBL] [Abstract][Full Text] [Related]
5. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
6. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K antagonists and emergencies.
Lapostolle F; Siguret V; Martin AC; Pailleret C; Vigué B; Zerbib Y; Tazarourte K
Eur J Emerg Med; 2018 Dec; 25(6):378-386. PubMed ID: 29462053
[TBL] [Abstract][Full Text] [Related]
8. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
[TBL] [Abstract][Full Text] [Related]
10. [Vitamin K antagonist, direct oral anticoagulants: Where is the truth?].
Laroche JP; Schved JF
J Mal Vasc; 2016 Dec; 41(6):383-388. PubMed ID: 27817997
[TBL] [Abstract][Full Text] [Related]
11. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
12. [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
Sucker C; Litmathe J; Berthold HK
MMW Fortschr Med; 2019 Oct; 161(Suppl 6):15-23. PubMed ID: 31587168
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
[TBL] [Abstract][Full Text] [Related]
14. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
[TBL] [Abstract][Full Text] [Related]
15. [Educational and information needs of patients under vitamin K antagonist therapy].
Ben Jeddou K; Ben M'Barka F; Boukhris I; Arfaoui H; Baccar H; Khalfalah N; Ouhachi Z
Rev Med Interne; 2018 Jul; 39(7):546-550. PubMed ID: 29789192
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulant treatment - evaluating the knowledge of patients admitted in physical medicine and rehabilitation units.
Janoly-Duménil A; Bourne C; Loiseau K; Luauté J; Sancho PO; Ciancia S; Caillet F; Boisson D; Rioufol C; Plauchu MM; Rode G; Jacquin-Courtois S
Ann Phys Rehabil Med; 2011 May; 54(3):172-80. PubMed ID: 21474406
[TBL] [Abstract][Full Text] [Related]
17. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
18. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.
Riva N; Ageno W
Semin Thromb Hemost; 2015 Mar; 41(2):178-87. PubMed ID: 25703519
[TBL] [Abstract][Full Text] [Related]
19. The role of dietary vitamin K in the management of oral vitamin K antagonists.
Holmes MV; Hunt BJ; Shearer MJ
Blood Rev; 2012 Jan; 26(1):1-14. PubMed ID: 21914559
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS; Lip GY
Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
